Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab: https://mms.businesswire.com/media/20210924005283/en/519367/5/GeNeuro_-_logo.jpg
GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab


GeNeuro (Paris:GNRO)(Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such

GeNeuro meldet erste Patientenrekrutierungen in allen fünf schweizerischen Zentren für die erste klinische Studie mit Temelimab zur personalisierten Medizin gegen Long COVID: https://mms.businesswire.com/media/20210924005283/en/519367/5/GeNeuro_-_logo.jpg
GeNeuro meldet erste Patientenrekrutierungen in allen fünf schweizerischen Zentren für die erste klinische Studie mit Temelimab zur personalisierten Medizin gegen Long COVID


GeNeuro (Euronext Paris: CH0308403085 - GNRO), ein biopharmazeutisches Unternehmen, das sich darauf konzentriert, die kausalen Faktoren zu stoppen, die das Fortschreiten von neurodegenerativen und

GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab: https://mms.businesswire.com/media/20210924005283/en/519367/5/GeNeuro_-_logo.jpg
GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab


GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple

Orascom Development Holding AG: has released its consolidated financial results for 9M 2022
Orascom Development Holding AG: has released its consolidated financial results for 9M 2022
Orascom Development Holding AG: has released its consolidated financial results for 9M 2022
Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission
Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission
Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission
Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China
Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China
Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China
Comet confirms growth targets at Capital Markets Day, short-term softening expected
Comet confirms growth targets at Capital Markets Day, short-term softening expected
Comet confirms growth targets at Capital Markets Day, short-term softening expected
EQS-News: Highlight Communications AG: Personnel
EQS-News: Highlight Communications AG: Personnel
EQS-News: Highlight Communications AG: Personnel
Highlight Event and Entertainment AG: Personnel
Highlight Event and Entertainment AG: Personnel
Highlight Event and Entertainment AG: Personnel
Cicor strengthens presence in Germany through the acquisition of Phoenix Mecano Digital Elektronik and Phoenix Mecano Digital Tunisie
Cicor strengthens presence in Germany through the acquisition of Phoenix Mecano Digital Elektronik and Phoenix Mecano Digital Tunisie
Cicor strengthens presence in Germany through the acquisition of Phoenix Mecano Digital Elektronik and Phoenix Mecano Digital Tunisie
Phoenix Mecano streamlines its Industrial Components business
Phoenix Mecano streamlines its Industrial Components business
Phoenix Mecano streamlines its Industrial Components business
First half results 2022/23: 
Growth in all regions and further progress on strategic initiatives
First half results 2022/23:  Growth in all regions and further progress on strategic initiatives
First half results 2022/23:  Growth in all regions and further progress on strategic initiatives
Orascom Development Holding AG:  announces its Egyptian Subsidiary (ODE) 9M 2022 Financial Results
Orascom Development Holding AG: announces its Egyptian Subsidiary (ODE) 9M 2022 Financial Results
Orascom Development Holding AG: announces its Egyptian Subsidiary (ODE) 9M 2022 Financial Results
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements
Edisun Power Europe AG: New solar plant of 23 MW starts solar power production
Edisun Power Europe AG: New solar plant of 23 MW starts solar power production
Edisun Power Europe AG: New solar plant of 23 MW starts solar power production
Partners Group acquires EdgeCore Digital Infrastructure, a hyperscale data center platform in the US
Partners Group acquires EdgeCore Digital Infrastructure, a hyperscale data center platform in the US
Partners Group acquires EdgeCore Digital Infrastructure, a hyperscale data center platform in the US
Partners Group to acquire Cloudflight, a leading digital transformation services provider
Partners Group to acquire Cloudflight, a leading digital transformation services provider
Partners Group to acquire Cloudflight, a leading digital transformation services provider
Implenia extends syndicated loan agreement and secures long-term financing
Implenia extends syndicated loan agreement and secures long-term financing
Implenia extends syndicated loan agreement and secures long-term financing
ZÜBLIN IMMOBILIEN HOLDING AG / Publication of Semi-Annual Report 2022/23 as of 30 September 2022
ZÜBLIN IMMOBILIEN HOLDING AG / Publication of Semi-Annual Report 2022/23 as of 30 September 2022
ZÜBLIN IMMOBILIEN HOLDING AG / Publication of Semi-Annual Report 2022/23 as of 30 September 2022
Evolva receives approval for Veri-teTM Resveratrol for animal health in Brazil
Evolva receives approval for Veri-teTM Resveratrol for animal health in Brazil
Evolva receives approval for Veri-teTM Resveratrol for animal health in Brazil
Swiss Steel Group saw expected slowdown in activity in Q3 2022
Swiss Steel Group saw expected slowdown in activity in Q3 2022
Swiss Steel Group saw expected slowdown in activity in Q3 2022
Meyer Burger successfully completes its capital increase of CHF 250 million
Meyer Burger successfully completes its capital increase of CHF 250 million
Meyer Burger successfully completes its capital increase of CHF 250 million
Meyer Burger announces 97.23 percent of the maximum number of offered shares were subscribed via the exercise of rights
Meyer Burger announces 97.23 percent of the maximum number of offered shares were subscribed via the exercise of rights
Meyer Burger announces 97.23 percent of the maximum number of offered shares were subscribed via the exercise of rights
Hudson Inks Expanded Agreement With Sunglass Hut To Operate New Standalone Travel Retail Stores in North America
Hudson Inks Expanded Agreement With Sunglass Hut To Operate New Standalone Travel Retail Stores in North America
Hudson Inks Expanded Agreement With Sunglass Hut To Operate New Standalone Travel Retail Stores in North America
Swiss Life increases fee income by 13% in the first three quarters of 2022
Swiss Life increases fee income by 13% in the first three quarters of 2022
Swiss Life increases fee income by 13% in the first three quarters of 2022